V2 Receptor Effects on Fluid Regulation and Performance

计划入组 10 人 · 首次发布于 2014 年 3 月 12 日

Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt

计划入组 12 人 · 首次发布于 2020 年 3 月 17 日

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

计划入组 88 人 · 首次发布于 2022 年 8 月 2 日

VYR-2020 + VYR-206

VIR-3434+ VIR-2218

VER-7835

Vir Biotechnology

United States

Vor Biopharma

United States

Tolvaptan Shows Promise as Universal Pharmacological Chaperone for Rare Disease Treatment

Vir Biotechnology's Combination Therapy for Hepatitis Delta Receives FDA Fast Track Designation

Vir Biotechnology's HDV Therapy Receives FDA Breakthrough Therapy Designation